Search - tctmd.com

Displaying 1 - 20 of 224

Sort: Relevancy | Date

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Yael L. Maxwell

January 23, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

News Daily News

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

Yael L. Maxwell

June 14, 2024

News Daily News

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

Michael O'Riordan

March 26, 2024

Advertisement

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Evolocumab Wins for Primary Prevention in VESALIUS-CV

DAPT De-escalation Success Varies by Sex: Meta-analysis

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

ACC/AHA Release New Comprehensive ACS Guidelines

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content